Search results for: Precision Medicine
Filter search results
OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?
16 January 2020
…touted as more efficient in testing new medicines. If accepted, this will change the whole process of regulating new medicines. The seminar will also discuss how personalised medicine threatens to…
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
31 March 2015
…are continually being made, information gaps remain. One such gap is the ability to monitor the use of medicines according to what the medicine has been used for (the ‘indication’)…
Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
1 June 2021
…key considerations for how they may need to be adapted for single-administration therapies. What is the process for approval and access to medicines? Regulators recommend the authorisation of a medicine…
Just Released: Health and the Use of Medicines in Wales
3 November 2011
…their medicines allocations, although the reasons remain unclear. At the same time, however, Wales lags behind England in the uptake of new primary and secondary care medicines that have received…
Comparing Prescription Medicines Prices in the UK to Prices in Other Countries
23 October 2012
…its most recent PPRS Report to Parliament, the Department of Health included the 250 top-selling branded medicines used in primary care in England in 2011; medicines used predominantly in the…
Economic Evaluation and Develop Medicines in the Development of Medicines
1 April 1988
…they give good value for money. Medicines have not been exempt from this process and there is increased emphasis on demonstrating additional benefit or social value from new medicines that…
New OHE Consulting Report: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
16 February 2017
…to identify the most suitable approach for assessing regenerative medicines, but rather to test whether regenerative medicines could fit into the existing pathway developed for conventional medicines. We suggest a…
Health and the Use of Medicines in Primary Care in Wales
1 November 2011
…their medicines allocations, although the reasons remain unclear. At the same time, however, Wales lags behind England in the uptake of new primary and secondary care medicines that have received…
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
1 September 2021
Medicines for rare and ultra-rare conditions face distinct economic and ethical challenges compared to medicines for more common conditions. These challenges are implicitly acknowledged by the National Institute of Health…